PTC Therapeutics, Inc. Restricted Cash, Noncurrent
PTC Therapeutics, Inc. (PTCT) had Restricted Cash, Noncurrent of $2.80 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:RestrictedCashNoncurrent · last filed 2026-07-30
- 2026-06-30: Restricted Cash, Noncurrent $2.80M.
- 2026-03-31: Restricted Cash, Noncurrent $2.80M.
| Period end | Restricted Cash, Noncurrent |
|---|---|
| 2026-06-30 | $2.80M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $2.80M 10-Q · filed 2026-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |